116 results on '"Rizzieri, David"'
Search Results
2. Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Author
-
Islam, Prioty, Rizzieri, David, Lin, Chenyu, de Castro, Carlos, Diehl, Louis, Li, Zhiguo, Moore, Joseph, Morris, Tod, and Beaven, Anne
- Subjects
- *
INDOLE compounds , *CLINICAL drug trials , *B cell lymphoma , *ANTINEOPLASTIC agents , *INVESTIGATIONAL drugs , *CANCER relapse , *TREATMENT effectiveness , *CELLULAR signal transduction , *EVEROLIMUS , *TRANSFERASES , *DRUG synergism , *HISTONE deacetylase , *DRUG development - Abstract
Novel therapeutics are needed for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Everolimus is an mTOR pathway inhibitor with synergistic anti-tumor activity when combined with histone deacetylase inhibitors, such as panobinostat, in preclinical lymphoma models. In this Phase II study, we evaluated overall response rate to single and combination everolimus and panobinostat in R/R DLBCL. Fifteen patients were enrolled to single-agent and 18 to combination. One patient responded to everolimus, while none responded to panobinostat. Though 25% of patients responded to combination therapy, responses were not durable with significant toxicity. We demonstrated minimal single-agent activity and prohibitive toxicity with combination therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
- Author
-
Pemmaraju, Naveen, Madanat, Yazan F., Rizzieri, David, Fazal, Salman, Rampal, Raajit, Mannis, Gabriel, Wang, Eunice S., Foran, James, and Lane, Andrew A.
- Subjects
- *
DENDRITIC cells , *ADVERSE health care events , *TUMORS - Abstract
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all patients with BPDCN. The CD123-directed therapy tagraxofusp is the only approved treatment for BPDCN; it was approved in the US as monotherapy for the treatment of patients aged ≥2 years with treatment-naive or relapsed/refractory BPDCN. Herein, we review the available data supporting the utility of tagraxofusp in treating patients with BPDCN. In addition, we present best practices and real-world insights from clinicians in academic and community settings in the US on how they use tagraxofusp to treat BPDCN. Several case studies illustrate the efficacy of tagraxofusp and discuss its safety profile, as well as the prevention, mitigation, and management of anticipated adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Dose‐intense chemoimmunotherapy plus radioimmunotherapy in high‐risk diffuse large B‐cell lymphoma and mantle cell lymphoma: a phase II study.
- Author
-
Hudson, Kathryn E., Rizzieri, David, Thomas, Samantha M., LeBlanc, Thomas W., Powell, Zachary, Diehl, Louis, Moore, Joseph O., DeCastro, Carlos, and Beaven, Anne W.
- Subjects
- *
MANTLE cell lymphoma , *RITUXIMAB , *RADIOIMMUNOTHERAPY , *LEUKOCYTE count - Abstract
The article offers information on a study related to dose-intense chemoimmunotherapy and radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma. It notes the three phases of treatment regimen induction 1, induction 2, and consolidation phase. It mentions the that this therapy is effective in patients with high-risk non-Hodgkin lymphoma (NHL) but is toxic.
- Published
- 2019
- Full Text
- View/download PDF
5. Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
- Author
-
Rizzieri, David
- Subjects
- *
LYMPHOPROLIFERATIVE disorders , *IMMUNOGLOBULIN G , *B cell lymphoma , *CD20 antigen , *IONIZING radiation , *RITUXIMAB , *DRUG efficacy , *THERAPEUTICS - Abstract
Non-Hodgkin’s lymphoma (NHL) comprises a clinically and biologically heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer (NK) cells. The disease course may range from indolent to aggressive. Zevalin ® (ibritumomab tiuxetan) is a radioactive drug product, which is the combination of a β-emitting isotope, 90 Y, linked to the anti-CD20 monoclonal antibody (mAb), rituximab. It has demonstrated therapeutic efficacy with durable responses and allows delivery of ionizing radiation directly to the tumor site, while minimizing toxicity to normal tissue. Ibritumomab tiuxetan is indicated for treatment of patients with relapsed or refractory low-grade, follicular NHL, including patients who are refractory to rituximab, and as consolidation therapy in previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy. Despite the efficacy and acceptable safety profile of ibritumomab tiuxetan, utilization has not been broadly adopted in practice due to a number of factors. This manuscript will review the literature available for ibritumomab tiuxetan, including several new trials that are currently being studied, and discuss the rationale for use of ibritumomab tiuxetan in NHL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
- Author
-
Rizzieri, David A., Cooley, Sarah, Odenike, Olatoyosi, Moonan, Lisette, Chow, Kay Hoong, Jackson, Kimberley, Wang, Xuejing, Brail, Leslie, and Borthakur, Gautam
- Subjects
- *
GLYCOGEN , *ACUTE leukemia , *RANITIDINE , *GLUCANS , *ANTIULCER drugs - Abstract
This open-label, Phase-2 study investigated the safety of LY2090314 (GSK-3 inhibitor) in AML patients. Twenty patients received 40-mg LY2090314 (50-mg ranitidine pretreatment) as follows: Cohort 1 – days 1, 8, and 15 of a 28-d cycle (n = 7); Cohort 2 – days 1, 5, and 9 of a 21-d cycle (n = 6); Cohort 3 – days 1, 5, 9, and 12 of a 21-d cycle (n = 7). Decreased appetite (n = 7) and nausea (n = 4) were the most frequently reported possibly drug-related non-hematologic treatment-emergent adverse events (TEAEs). Hematologic TEAEs included febrile neutropenia (n = 2), thrombocytopenia (n = 1), and anemia (n = 1). Atrial flutter (n = 1), QT interval prolongation (n = 3), and visual disturbances (n = 2) were observed, but were not clinically significant (investigator assessed). Although β-catenin levels indicated an on-target effect, no complete or partial remissions were observed. Pharmacokinetics were consistent with a previous Phase 1 study. These data suggest that single-agent LY2090314 has acceptable safety but limited clinical benefit in AML patients at the dose/frequencies investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.
- Author
-
Zahid, Mohammad Faizan and Rizzieri, David Alan
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *BLOOD diseases , *GRAFT versus host disease , *CORD blood , *BLOOD donors , *CYCLOPHOSPHAMIDE , *IMMUNOSUPPRESSION - Abstract
Despite the advent of targeted therapies and novel agents, allogeneic hematopoietic stem cell transplantation remains the only curative modality in the management of hematologic disorders. The necessity to find an HLA-matched related donor is a major obstacle that compromises the widespread application and development of this field. Matched unrelated donors and umbilical cord blood have emerged as alternative sources of donor stem cells; however, the cost of maintaining donor registries and cord blood banks is very high and even impractical in developing countries. Almost every patient has an HLA haploidentical relative in the family, meaning that haploidentical donors are potential sources of stem cells, especially in situations where cord blood or matched unrelated donors are not easily available. Due to the high rates of graft failure and graft-versus-host disease, haploidentical transplant was not considered a feasible option up until the late 20th century, when strategies such as “megadose stem cell infusions” and posttransplantation immunosuppression with cyclophosphamide showed the ability to overcome the HLA disparity barrier and significantly improve the rates of engraftment and reduce the incidence and severity of graft-versus-host disease. Newer technologies of graft manipulation have also yielded the same effects in addition to preserving the antileukemic cells in the donor graft. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Immunotherapeutic Applications of NK Cells.
- Author
-
Davis, Carter T. and Rizzieri, David
- Subjects
- *
REGENERATION (Biology) , *ACUTE myeloid leukemia diagnosis , *KILLER cells , *ACUTE myeloid leukemia treatment , *HEMATOPOIETIC stem cell transplantation , *CELLULAR therapy , *LEUKEMIA treatment , *PHYSIOLOGY - Abstract
Natural Killer (NK) cells are lymphoid cells that exhibit an innate response against virus-infected cells. These cells are also capable of mounting an immune response against tumor cells after education through major histocompatibility complex (MHC) class I molecules. NK cell regulation is mediated through IFN-gamma and IL-15, important cytokines which can drive NK cell expansion in vivo. Previous studies have shown effective infusion of allogeneic NK cells after lymphodepleting regimens with induction of remission of poor prognosis acute myeloid leukemia (AML). Challenges remain in the expansion of these NK cells once infused and in their education to recognize tumor targets. A principal mechanism of tumor recognition is through KIR mismatch in cells lacking self MHC I molecules. Activating KIRs exist, though their ligands are unknown at this time. Impacting NK cell expansion and education in vivo has been challenging, and thus far clinical applications of NK cells have shown promise in helping to maintain remission in humans, though this remission has not been maintained. Future efforts to utilize NK cells clinically are focusing on developing more consistency in successful expansion of NK cell and educating them to recognize their tumor targets. Additional efforts to utilize novel antibody-based therapy to engage NK cells to their tumor targets are also in development. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
- Author
-
Rizzieri, David, Vey, Norbert, Thomas, Xavier, Huguet-Rigal, Françoise, Schlenk, Richard F., Krauter, Jürgen, Kindler, Thomas, Gjertsen, Bjørn Tore, Blau, Igor Wolfgang, Jacobsen, Tove Flem, Johansen, Malin, Bergeland, Trygve, Gianella-Borradori, Athos, and Krug, Utz
- Subjects
- *
PROTEIN expression , *NUCLEOSIDE transport proteins , *CYTARABINE , *ESTER derivatives , *CLINICAL drug trials , *DOSE-response relationship in biochemistry - Abstract
Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was manageable. There is a trend suggesting that hENT1 expression influences response to cytarabine, but not sufficient to support it as a biomarker for guiding treatment. Further, we conclude that the activity of elacytarabine is not significantly predicted by the hENT1 expression level. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
- Author
-
Rizzieri, David A., Johnson, Jeffrey L., Byrd, John C., Lozanski, Gerard, Blum, Kristie A., Powell, Bayard L., Shea, Thomas C., Nattam, Sreenivasa, Hoke, Eva, Cheson, Bruce D., and Larson, Richard A.
- Subjects
- *
RITUXIMAB , *DRUG efficacy , *CANCER chemotherapy , *LYMPHOMAS , *LEUKEMIA , *MEDICAL statistics - Abstract
To improve long-term outcomes for Burkitt leukaemia/lymphoma ( BL) or aggressive lymphomas in adults, we assessed the benefit of adding rituximab and filgrastim support to a dose-dense modified chemotherapy regimen from the Cancer and Leukemia Group B ( CALGB) 9251 trial. One hundred and five patients (aged 19-79 years) were enrolled; 27% were >60 years old; 47% had high or high-intermediate risk by International Prognostic Index ( IPI) criteria. Common severe toxicities included stomatitis/upper gastrointestinal toxicity (69%), renal insufficiency (10%), neurological events (25%) and pulmonary events (18%). Seven died from treatment-related causes (one central nervous system bleed, four infections, two respiratory failure); five were >60 years old. Results in this adult population are encouraging as complete response ( CR) was observed in 83% and 4-year event-free ( EFS) and overall survivals ( OS) were 74% and 78%, respectively. Results compare favourably to our prior chemotherapy alone study ( CALGB 9251) but despite this, high-risk patients still had worse outcomes. In conclusion, short duration, intensive chemo-immunotherapy is feasible and should be considered in adults with BL as it results in high remission rates and durable remissions. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
- Author
-
Brander, Danielle, Rizzieri, David, Gockerman, Jon, Diehl, Louis, Shea, Thomas Charles, Decastro, Carlos, Moore, Joseph O., and Beaven, Anne
- Subjects
- *
HEALTH outcome assessment , *LYMPHOMA treatment , *B cell lymphoma , *VASCULAR endothelial growth factors , *CHEMICAL inhibitors , *THERAPEUTICS - Abstract
PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patients were evaluable for response: one patient had a complete response (CR), six patients had stable disease but subsequently progressed, 10 patients had progressive disease by three cycles and one subject withdrew before response evaluation. The patient who attained a CR underwent autologous stem cell transplant and remains disease-free 76 months after study completion. There were no grade 4 toxicities. Grade 3 thrombocytopenia occurred in 20% and grade 3 hypertension occurred in 10%. There were no episodes of grade 3 proteinuria. In conclusion, PTK787/ZK222584 was well tolerated in a heavily pretreated population of patients with DLBCL, although its therapeutic potential as a single agent in DLBCL appears limited. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
- Author
-
Held, Lauren A., Rizzieri, David, Long, Gwynn D., Gockerman, Jon P., Diehl, Louis F., Castro, Carlos M. de, Moore, Joseph O., Horwitz, Mitchell E., Chao, Nelson J., and Gasparetto, Cristina
- Subjects
- *
THERAPEUTIC use of vitamin C , *ARSENIC trioxide , *MULTIPLE myeloma treatment , *MULTIPLE myeloma , *HEALTH facilities , *CELLULAR therapy , *CLINICAL trials , *FEASIBILITY studies , *PATIENTS , *THERAPEUTICS - Abstract
Purpose: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcade™) (AAV) for patients with relapsed/refractory multiple myeloma. Experimental Design: ATO (0.25 mg/kg) and AA (1 g) were given with an escalating dose of bortezomib (1 mg/m2 or 1.3 mg/m2 IV bolus on days 1 and 8 of a 21-day cycle). Results: Ten patients (median age 62 years), with a median of 3 prior regimens, were enrolled. Four (40%) patients achieved clinical benefit, with one patient achieving a durable partial response. No formal DLTs were encountered. Conclusion: AAV combination was feasible and demonstrated some benefits in this heavily pretreated population. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
- Author
-
Lin, Chenyu, Galal, Ahmed, Rizzieri, David, Chawla, Sant, Lee, Seung T., Georgy, Angela, Dabovic, Kristina, Strack, Thomas, and McKinney, Matthew
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *DRUG efficacy , *CAPILLARY leak syndrome , *B cell lymphoma , *CANCER relapse , *DISEASE incidence , *GEMCITABINE , *TREATMENT effectiveness , *RESEARCH funding , *GENETIC engineering , *DESCRIPTIVE statistics , *OXALIPLATIN , *BACTERIAL toxins , *PROGRESSION-free survival , *DRUG toxicity , *RECOMBINANT proteins , *EVALUATION - Abstract
MT-3724 is an engineered direct-kill immunotoxin comprised of a CD20-specific scFv fused to a Shiga-like toxin subunit. In this phase IIa study, eight patients with relapsed diffuse large B-cell lymphoma were treated with MT-3724 combined with gemcitabine and oxaliplatin (GEMOX). The objective response rate was 85.7%, with a median duration of response of 2.2 months. The 12-month overall survival and progression-free survival were 71.4% and 28.6%, respectively. Two patients experienced grade 2 capillary leak syndrome (CLS). Combination therapy with MT-3724 and GEMOX demonstrated an early efficacy signal but was limited by the incidence of CLS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.
- Author
-
O'Brien, Susan, Rizzieri, David A., Vey, Norbert, Ravandi, Farhad, Krug, Utz O., Sekeres, Mikkael A., Dennis, Mike, Venditti, Adriano, Berry, Donald A., Jacobsen, Tove Flem, Staudacher, Karin, Bergeland, Trygve, and Giles, Francis J.
- Subjects
- *
ACUTE myeloid leukemia , *CYTARABINE , *CELL-mediated cytotoxicity , *NUCLEOSIDE transport proteins , *DISEASE remission , *ESTERIFICATION - Abstract
Elacytarabine is a novel cytotoxic nucleoside analogue, independent of nucleoside transporters (e.g. human Equilibrative Nucleoside Transporter 1 [ hENT1]) for cell uptake, and mechanisms of action similar to those of cytarabine. This Phase II study assessed the efficacy and safety of elacytarabine in patients with advanced stage acute myeloid leukaemia ( AML). Patients received 2000 mg/m2 per d continuously i.v. during days 1-5 every 3 weeks. Patients were matched by six risk factors with historical controls; remission rate (assessed after 1 or 2 cycles) and 6-month survival were compared. Sixty-one patients, median age 58 years, were enrolled; 52% had five or six risk factors. The remission rate was 18% (95% confidence interval: 9-30%) vs. 4% in controls ( P < 0·0001), 6-month survival rate was 43%, median overall survival was 5·3 months (vs. 1·5 months); 10 patients (16%) were referred for stem cell transplantation after treatment. Side effects were predictable and manageable. The most common grade 3/4 non-haematological adverse events were febrile neutropenia, hypokalemia, fatigue, hyponatraemia, dyspnoea and pyrexia. Thirty-day all-cause mortality, after start of treatment, was 13% vs. 25% in controls. Elacytarabine has monotherapy activity in patients with advanced AML. This study provides proof-of-concept that lipid esterification of nucleoside analogues is clinically relevant. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning
- Author
-
Kanda, Junya, Rizzieri, David A., Gasparetto, Cristina, Long, Gwynn D., Chute, John P., Sullivan, Keith M., Morris, Ashley, Smith, Clayton A., Hogge, Donna E., Nitta, Janet, Song, Kevin, Niedzwiecki, Donna, Chao, Nelson J., and Horwitz, Mitchell E.
- Subjects
- *
BLOOD transfusion , *HLA histocompatibility antigens , *FLUDARABINE , *DEATH rate , *HEMATOLOGICAL oncology , *CONFIDENCE intervals , *COMPLICATIONS from organ transplantation , *FOLLOW-up studies (Medicine) , *CLINICAL trials - Abstract
High treatment-related mortality (TRM) and high graft failure rate are serious concerns in HLA-mismatched umbilical cord blood (UCB) transplantation with myeloablative conditioning. We conducted a prospective trial of dual UCB transplantation using modified myeloablation consisting of total-body irradiation (TBI; 1350 cGy) and fludarabine (Flu) (160 mg/m2). Twenty-seven patients (median age, 33 years; range: 20-58 years) with hematologic malignancies were enrolled. The median combined cryopreserved total nucleated cell (TNC) dose was 4.3 × 107/kg (range: 3.2-7.7 × 107/kg). The cumulative incidences of neutrophil (≥500/μL) and platelet (≥50,000/μL) engraftment were 80% (95% confidence interval [CI], 58%-91%) and 68% (95% CI, 46%-83%), respectively. Among engrafted patients, a single cord blood unit was predominant by 100 days posttransplantation. A higher cryopreserved and infused TNC dose and infused CD3+ cell dose were significant factors associated with the predominant UCB unit (P = .032, .020, and .042, respectively). TRM and relapse rates at 2 years were 28% (95% CI, 12%-47%) and 20% (95% CI, 7%-37%), respectively. Cumulative incidences of grades II–IV and grades III–IV acute graft-versus-host disease (aGVHD) were 37% (95% CI, 20%-55%) and 11% (95% CI, 3%-26%), respectively, and that of chronic GVHD was 31% (95% CI, 15%-49%). With a median follow-up of 23 months, overall survival and disease-free survival rates at 2 years were 58% (95% CI, 34%-75%) and 52% (95% CI, 29%-70%), respectively. This study supports the use of TBI 1350 cGy/Flu as an alternative to conventional myeloablative conditioning for dual UCB transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
16. Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors.
- Author
-
Rizzieri, David A., Crout, Christopher, Storms, Robert, Golob, Jared, Long, Gwynn D., Gasparetto, Cristina, Sullivan, Keith M., Horwitz, Mitchell, Chute, John, Lagoo, Anand S., Morris, Ashley, Beaven, Anne, Yang, Yiping, Peterson, Bercedis, Li, Zhiguo, and Chao, Nelson J.
- Subjects
- *
CANCER chemotherapy , *LEUKEMIA , *INTERLEUKIN-2 , *T cells , *HLA histocompatibility antigens , *CANCER relapse , *FOLLOW-up studies (Medicine) , *HEMATOPOIETIC stem cells , *STEM cell transplantation - Abstract
Introduction: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the feasibility of administering IL-2 following a T-cell-depleted nonmyeloablative hematopoietic stem cell transplant. Methods: Patients received T-cell-depleted nonmyeloablative transplant from a matched or mismatched related donor. Those with allogeneic engraftment < grade 2 acute GVHD at time of study entry, and no severe end organ damage were eligible and received IL-2 starting 6 weeks after the first day of stem cell infusion. Patients received 1 mu/m2 daily for 5 days each week for 4 weeks followed by a 2-week rest period for a 6-week cycle to continue for up to 1 year. Results: Eight patients aged 28–69 years were treated. Significant toxicities were limited to GVHD of the skin ≤grade 2 in 3 patients and severe fatigue in 4 patients, limiting the duration of therapy. Two of the 8 patients died of relapsed disease and 1 from CMV. With a median overall duration of follow-up of survivors of 48 months, 5 patients (63%) remain alive and in continuous complete remission. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation
- Author
-
Rizzieri, David A., Storms, Robert, Chen, Dong-Feng, Long, Gwynn, Yang, Yiping, Nikcevich, Daniel A., Gasparetto, Cristina, Horwitz, Mitchell, Chute, John, Sullivan, Keith, Hennig, Therese, Misra, Debashish, Apple, Christine, Baker, Megan, Morris, Ashley, Green, Patrick G., Hasselblad, Vic, and Chao, Nelson J.
- Subjects
- *
KILLER cells , *STEM cell transplantation , *LYMPHOCYTES , *HLA histocompatibility antigens , *GRAFT versus host disease , *DISEASE relapse , *INFECTION , *STANDARD deviations - Abstract
Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients following a 3-6/6 HLA matched T cell-depleted nonmyeloablative allogeneic transplant. The primary endpoint of this study was feasibility and safety. Eight weeks following transplantation, donor NK cell-enriched DLIs were processed using a CD56+ selecting column with up to 3 fresh infusions allowed. Toxicity, relapse, and survival were monitored. T cell phenotype, NK cell functional recovery, and KIR typing were assessed for association with outcomes. Fourteen matched and 16 mismatched transplanted patients received a total of 51 NK cell-enriched DLIs. Selection resulted in 96% (standard deviation [SD] 8%) purity and 83% (SD 21%) yield in the matched setting and 97% (SD 3%) purity and 77% (SD 24%) yield in the mismatched setting. The median number of CD3− CD56+ NK cells infused was 10.6 (SD 7.91) × 106 cells/kg and 9.21 (SD 5.6) × 106 cells/kg, respectively. The median number of contaminating CD3+CD56− T cells infused was .53 (1.1) × 106 and .27 (.78) × 106 in the matched and mismatched setting, respectively. Only 1 patient each in the matched (n = 14) or mismatched (n = 16) setting experienced severe aGVHD with little other toxicity attributable to the infusions. Long-term responders with multiple NK cell-enriched infusions and improved T cell phenotypic recovery had improved duration of responses (p = .0045) and overall survival (OS) (P = .0058). A 1-step, high-yield process is feasible, and results in high doses of NK cells infused with little toxicity. NK cell-enriched DLIs result in improved immune recovery and outcomes for some. Future studies must assess whether the improved outcomes are the direct result of the high doses and improved NK cell function or other aspects of immune recovery. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
18. Outcomes of Patients Who Undergo Aggressive Induction Therapy for Secondary Acute Myeloid Leukemia.
- Author
-
Rizzieri, David A., O'Brien, Jenny A., Broadwater, Gloria, Decastro, Carlos M., Dev, Prakash, Diehl, Louis, Beaven, Anne, Lagoo, Anand, Gockerman, Jon P., Chao, Nelson J., and Moore, Joseph O.
- Subjects
- *
DRUG efficacy , *DRUG therapy , *HEALTH outcome assessment , *CANCER chemotherapy , *LEUKEMIA , *CHRONIC myeloid leukemia , *DISEASE remission , *PATIENTS - Abstract
The article presents a study that reviews survival of secondary acute myeloid leukemia (SAML) patients receiving aggressive induction chemotherapy. The study shows that the overall survival was 13.6 months and median event-free survival was eight months. It reveals that eight patients passed away shortly after receiving induction therapy due to side effects or the disease. It indicates that the median disease-free survival for patients attaining morphologic complete remission was nine months.
- Published
- 2009
- Full Text
- View/download PDF
19. Allogeneic Hematopoietic Stem Cell Transplant Using Mismatched/Haploidentical Donors
- Author
-
Koh, Liang-Piu, Rizzieri, David A., and Chao, Nelson J.
- Subjects
- *
STEM cells , *GRAFT versus host disease , *HEMATOPOIETIC stem cells , *BLOOD cells - Abstract
Abstract: Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for nearly all patients to benefit from HSCT when a human leukocyte antigen (HLA) genotypically matched sibling is not available. Initial results with the use of mismatched allografts led to limited enthusiasm because of graft-versus-host disease (GVHD) and infectious complications, resulting in an unacceptable treatment-related morbidity and mortality. Recent advances with effective T cell depletion, the use of a “megadose” of stem cells, earlier detection of severe infections, combined with better antimicrobial therapy and reduced-intensity conditioning (RIC) has significantly decreased the early transplant-related mortality and GVHD, whereas enabling prompt engraftment, hence advancing the therapeutic benefit of haploidentical transplantation. However, the cardinal problems related to delayed immune reconstitution allowing posttransplant infectious complications and relapse remain, limiting the efficacy of haploidentical HSCT. Preliminary data has demonstrated the potential for use of adoptive cellular immunity and selective allodepletion in rapidly reconstituting immunity without GVHD. The encouraging reports from haploidentical transplant using noninherited maternal antigen (NIMA)-mismatched or natural killer (NK) alloreactive donors may greatly increase the donor availability and open the way to more appropriate donor selection in HLA-haploidentical HSCT. Future challenges remain in determining the safest approach for haploidentical transplant to be performed with minimal risk of GVHD, whereas preserving effective graft-versus-leukemia activity and promoting prompt immune reconstitution. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
20. Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis.
- Author
-
Rizzieri, David A, Schiller, Gary J., Solomon, Scott R., Newell, Laura F., Erba, Harry P., Ryan, Robert J., Faderl, Stefan, Cortes, Jorge E., and Lancet, Jeffrey E.
- Subjects
- *
ACUTE myeloid leukemia , *LIPOSOMES , *SUMATRIPTAN , *PACLITAXEL , *CELL transplantation , *RADIOTHERAPY , *ODDS ratio - Abstract
t-AML arises from prior cytotoxic therapy, ionizing radiotherapy, or immunosuppressive therapy for an unrelated disease and is associated with poorer outcomes relative to de novo AML, with a median overall survival (OS) of ∼6 mo following conventional chemotherapy. CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D] at a synergistic ratio, is approved by the FDA and EMA for the treatment of adults with newly diagnosed t-AML or AML with myelodysplasia-related changes. In a phase 3 study (NCT01696084) in older patients (pts; 60-75 y) with newly diagnosed high-risk/secondary AML, CPX-351 significantly improved OS vs 7+3, with a comparable safety profile. An exploratory analysis of the phase 3 study compared outcomes in the subgroup of pts with t-AML who achieved complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi). Pts were randomized 1:1 to receive 1-2 induction cycles with CPX-351 (100 units/m2 [C 100 mg/m2 + D 44 mg/m2] as a 90-min infusion on Days 1, 3, and 5 [2nd induction: Days 1 and 3]) or 7+3 (C 100 mg/m2/day continuously for 7 d [2nd induction: 5 d] + D 60 mg/m2 on Days 1-3 [2nd induction: Days 1-2]). Pts achieving CR+CRi could receive up to 2 consolidation cycles with CPX-351 (65 units/m2 [C 65 mg/m2 + D 29 mg/m2] on Days 1 and 3) or 5+2 (as in 2nd induction). Pts could receive hematopoietic cell transplantation (HCT) at the physician's discretion. t-AML was diagnosed in 63/309 (20%) enrolled pts; 14/30 (47%) receiving CPX-351 and 12/33 (36%) receiving 7+3 achieved a CR+CRi (odds ratio = 1.53 [95% CI: 0.56-4.20]). Fewer pts with CR+CRi after CPX-351 vs 7+3 had received prior non-anthracycline chemotherapy alone (CPX-351: 2 [14%] vs 7+3: 5 [42%]), whereas prior radiation therapy alone was less frequent in 7+3 pts (5 [36%] vs 2 [17%]). Median OS was longer for CPX-351 vs 7+3 in t-AML pts with CR+CRi (Figure 1). The HCT rate in pts with CR+CRi was similar for CPX-351 and 7+3 (57% vs 58%; relative risk = 0.97 [95% CI: 0.50-1.90]); however, OS landmarked from the HCT date was longer for CPX-351 (Figure 2). No pt relapsed prior to HCT. Median OS in pts with CR+CRi but no HCT was not reached for CPX-351 vs 8.48 mo for 7+3. The safety profile of CPX-351 vs 7+3 is shown in Table 1. Among t-AML pts who achieved CR+CRi, CPX-351 improved median OS overall and OS landmarked from the HCT date vs 7+3. The CPX-351 safety profile in this subgroup was generally consistent with the known profile of 7+3. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.
- Author
-
Rizzieri, David A., Wadleigh, Martha, Wikstrand, Carol J., Mann, Karen P., Sen, Filiz, Peterson, Bercedis L., Niedzwiecki, Donna, Proia, Alan D., and Bigner, Darell D.
- Subjects
- *
TENASCIN , *EXTRACELLULAR matrix proteins , *LYMPHOMAS , *RETICULOENDOTHELIAL granulomas , *LYMPHOPROLIFERATIVE disorders - Abstract
This study investigated stromal changes in expression of tenascin and vasculogenesis in lymphoma. Documenting the dynamic nature of the stromal changes in lymphoma in relation to response to therapy is helpful in planning new therapies directed at these targets. Two hundred and sixty one samples from 111 patients with varying types of non-Hodgkin's lymphoma were reviewed and examined using immunohistochemistry techniques. Samples were stained for factor VIII – related antigen for microvessel density (MVD) analysis and anti-tenascin antibody for qualitative assessment of the stromal expression. Multiple samples from the same patient were taken at the same point in time to assess whether stromal changes were limited to sites of disease. Multiple samples were examined over the course of a patient's illness to assess whether the stromal changes were modulated according to disease activity. There was a significant increase in tenascin expression and MVD in the sites of disease compared with uninvolved sites ( p = 0.01 and p [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
22. 4-Hydroperoxycyclophosphamide–purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia
- Author
-
Rizzieri, David A., Talbot, Jeffrey T., Long, Gwynn D., Vredenburgh, James J., Gasparetto, Christina, Smith, Clayton S., Colvin, Michael O., Adams, David, Morris, Ashley, Dodge, Richard, Loftis, Jennifer, Waters-Pick, Barbara, Reese, Melissa, Carawan, Helen, Koh, Liang Piu, and Chao, Nelson J.
- Subjects
- *
CELLS , *ANTINEOPLASTIC agents , *BONE marrow , *MYELOID leukemia - Abstract
Abstract: We have performed a phase I dose escalation of 4-Hydroperoxycyclophosphamide (4HC) purging of autologous peripheral blood progenitor cells (PBPCs) to improve the outcome of autologous transplantation for patients with myeloid leukemia. Peripheral blood stem cells were mobilized after cytosine arabinoside of 2 g/m2 every 12 hours × 8 doses with etoposide of 40 mg/kg total dose infused over 4 days, followed by growth factor support. The preparative regimen included Busulfan of 1 mg/kg orally every 6 hours × 16 doses, followed by etoposide of 60 mg/kg × 1 day (the patient with chronic myeloid leukemia received cyclophosphamide of 60 mg/kg/d × 2 days in lieu of etoposide). PBPCs purged with 4HC were infused following this induction. Toxicities included grade 3 or 4 skin rashes, stomatitis/mucositis, and delay in time to hematopoietic recovery. The maximum tolerated dose of 4HC used to purge PBPCs in this trial was 20 μg/mL, which resulted in an average of 18 days for white blood cells and 28 days for platelet recovery. With a median follow-up of 2.25 years in surviving patients, the 3-year disease free survival rate is 44% and the overall survival rate is 89%. These data suggest that autologous PBPCs are more sensitive than marrow purged with 4HC, tolerating less intense purging, although a survival advantage may still be seen and should be assessed in larger studies. Approaches to minimize stomatitis and protect normal stem cells from the toxicity of 4HC may improve the tolerance and efficacy of this approach. © 2003 American Society for Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation 9:183-188 (2003) [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
23. MDS: unraveling the mystery.
- Author
-
Rizzieri, David A.
- Subjects
- *
AZACITIDINE , *MYELODYSPLASTIC syndromes treatment , *COMBINATION drug therapy , *CLINICAL trials , *PATIENTS - Abstract
The author comments on a phase 2 study by Sekeres and colleagues of lenalidomide and azacitidine for higher risk myelodysplastic syndromes (MDS). The author argues that high overall response and duration or response supports, combination and multitargeted approaches for the disease rather than chemotherapeutics. The author contends that the study by Sekeres which were correlated with comprehensive genetic analysis of their subjects is needed to increase targeted therapy options.
- Published
- 2012
- Full Text
- View/download PDF
24. Pulmonary Sarcoidosis Following Stem Cell Transplantation.
- Author
-
Bhagat, Rajesh, Rizzieri, David A., Vredenburgh, James J., Chao, Nelson J., and Folz, Rodney J.
- Subjects
- *
LYMPHOPROLIFERATIVE disorders , *SARCOIDOSIS , *STEM cell transplantation , *TUMORS , *LUNG diseases - Abstract
Noninfectious pulmonary complications are one of the major side effects of hematopoetic stem cell transplant (HSCT); however, the development of pulmonary sarcoidosis post-HSCT is uncommon, with only three cases previously reported. In each of those cases, sarcoidosis was also diagnosed in the stem cell donor. We now report four cases of de novo pulmonary sarcoidosis occurring post-HSCT (3 autologous HSCT and 1 allogeneic HSCT). We suggest that pulmonary sarcoidosis may develop following either autologous or allogeneic HSCT, and the prevalence may be 10-fold higher than that of the normal population. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
25. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
- Author
-
Stein, Eytan M., de Botton, Stephane, Cluzeau, Thomas, Pigneux, Arnaud, Liesveld, Jane L., Cook, Rachel J., Rousselot, Philippe, Rizzieri, David A., Braun, Thorsten, Roboz, Gail J., Lebon, Delphine, Heiblig, Mael, Baker, Kristen, Volkert, Angela, Paul, Sofia, Rajagopal, Nisha, Roth, David A., Kelly, Michael, and Peterlin, Pierre
- Subjects
- *
GENETIC overexpression , *RETINOIC acid receptors , *ACUTE myeloid leukemia , *AZACITIDINE , *MYELODYSPLASTIC syndromes - Abstract
Tamibarotene-based therapy is a novel targeted approach for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with retinoic acid receptor alpha (RARA) gene overexpression. Approximately, 50% of higher-risk myelodysplastic syndrome (MDS) patients and approximately 30% of AML patients are positive for RARA overexpression using a blood-based biomarker test that measures RARA expression in peripheral blasts. A phase 2 study investigating the activity of tamibarotene in patients with RARA overexpression was conducted in patients with AML and MDS (NCT02807558). In 28 patients with R/R AML and RARA overexpression treated with tamibarotene in combination with azacitidine, the median overall survival was 5.9 months. In 21 response-evaluable patients, the complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate was 19%, and median time to initial CR/CRi was 1.2 months. The favorable safety profile and preliminary clinical activity support the development of combination therapies with tamibarotene in myeloid malignancies with RARA overexpression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Is Timing Everything?
- Author
-
Rizzieri, David
- Published
- 2014
- Full Text
- View/download PDF
27. Clinical and Immunomodulatiory Outcomes of Microtransplantation for AML.
- Author
-
Rizzieri, David A., Rao, Arati V., Beaven, Anne, Brander, Danielle, DeCastro, Carlos, Diehl, Louis, LeBlanc, Thomas W., Long, Gwynn D., McKinney, Matthew, Toaso, Bonnie, Chao, Nelson J., and Sung, Anthony D.
- Subjects
- *
IMMUNOREGULATION , *HEALTH outcome assessment , *ACUTE myeloid leukemia , *CLINICAL trials , *MEDICAL care - Published
- 2016
- Full Text
- View/download PDF
28. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
- Author
-
Stein, Eytan M., Garcia-Manero, Guillermo, Rizzieri, David A., Tibes, Raoul, Berdeja, Jesus G., Savona, Michael R., Jongen-Lavrenic, Mojca, Altman, Jessica K., Thomson, Blythe, Blakemore, Stephen J., Daigle, Scott R., Waters, Nigel J., Suttle, A. Benjamin, Clawson, Alicia, Pollock, Roy, Krivtsov, Andrei, Armstrong, Scott A., DiMartino, Jorge, Hedrick, Eric, and Löwenberg, Bob
- Subjects
- *
HISTONE methyltransferases , *LEUKEMIA , *CONSTIPATION , *NEUTROPENIA , *METHYLATION , *FATIGUE (Physiology) - Abstract
Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involving mixed lineage leukemia (MLL) gene rearrangements (MLL-r) resulting from 11q23 translocations. Fifty-one patients were enrolled into 6 dose-escalation cohorts (n = 26) and 2 expansion cohorts (n = 25) at pinometostat doses of 54 and 90 mg/m2 per day by continuous intravenous infusion in 28-day cycles. Because a maximum tolerated dose was not established in the dose-escalation phase, the expansion doses were selected based on safety and clinical response data combined with pharmacodynamic evidence of reduction in H3K79 methylation during dose escalation. Across all dose levels, plasma pinometostat concentrations increased in an approximately dose-proportional fashion, reaching an apparent steady-state by 4-8 hours after infusion, and rapidly decreased following treatment cessation. The most common adverse events, of any cause, were fatigue (39%), nausea (39%), constipation (35%), and febrile neutropenia (35%). Overall, 2 patients, both with t(11;19), experienced complete remission at 54 mg/m2 per day by continuous intravenous infusion, demonstrating proof of concept for delivering clinically meaningful responses through targeting DOT1L using the single agent pinometostat in MLL-r leukemia patients. Administration of pinometostat was generally safe, with the maximum tolerated dose not being reached, although efficacy as a single agent was modest. This study demonstrates the therapeutic potential for targeting DOT1L in MLL-r leukemia and lays the groundwork for future combination approaches in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor.
- Author
-
Rizzieri, David A. and Liu, Jane
- Subjects
- *
HERPESVIRUS disease treatment , *THERAPEUTIC use of protease inhibitors - Abstract
Discusses the treatment of a patient with human herpesvirus 8 (HHV-8) with a protease inhibitor. The case of an individual diagnosed with HIV-1 infection in 1990.
- Published
- 1997
- Full Text
- View/download PDF
30. Fatigue: A Long Standing Symptom Affecting Quality of Life in Patients Following Hematopoietic Cell Transplantation
- Author
-
Hennig, Therese, Rizzieri, David, Abernathy, Amy, Helms, Tanya, and Chao, Nelson J.
- Published
- 2013
- Full Text
- View/download PDF
31. Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia
- Author
-
Giles, Francis, Rizzieri, David, Ravandi, Farhad, Swords, Ronan, Jacobsen, Tove Flem, and O’Brien, Susan
- Published
- 2012
- Full Text
- View/download PDF
32. Real‐world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.
- Author
-
Strand, Andrew M., Alexander, Barbara D., Sarpong, Eric, Wong, Jessica Retuerto, Engemann, Ashley, Rizzieri, David, Wu, Yuan, and Johnson, Melissa D.
- Subjects
- *
PREVENTIVE medicine , *LYMPHOCYTIC leukemia , *INDUCTION chemotherapy , *ACUTE leukemia , *MYELODYSPLASTIC syndromes , *INVASIVE candidiasis - Abstract
Background and Objectives: Patients undergoing induction/reinduction chemotherapy for haematologic malignancies (HM) are at risk for invasive fungal infections (IFIs). In 2015, Duke University Hospital (DUH) implemented a new standardised fungal prophylaxis protocol for adult patients undergoing induction chemotherapy for acute lymphocytic leukaemia, acute myelocytic leukaemia and myelodysplastic syndrome. This study assessed the impact of protocol implementation on (1) use of antifungal prophylaxis, throughout the at‐risk period and (2) patient outcomes such as IFI and mortality. Methods: Retrospective, observational study of adult HM patients admitted to DUH for induction/reinduction chemotherapy pre‐ (7/1/2013–12/31/2014) and post‐ (1/1/2015–10/31/2016) implementation of standardised antifungal prophylaxis protocol (which recommended posaconazole as the first‐line agent). Patients were followed for up to 100 days after initiation of induction chemotherapy to evaluate use of antifungal prophylaxis and patient outcomes. Results: 218 patients with haematologic malignancies were included (90 pre, 128 post). Use of antifungal prophylaxis increased from 81.1% (pre) to 97.7% (post) (p <.0001). Overall, 71% received posaconazole as initial antifungal prophylaxis (64.4% pre, 75.7% post). Approximately one‐fourth of patients (25.6%, pre vs 26.6%, post) developed an IFI (proven/probable or possible using modified EORTC definitions) (p =.868); 100‐day mortality remained stable (18.9% pre vs 18.8% post, respectively, p =.979). Lack of antifungal prophylaxis and older age (≥60 years) were associated with higher risk of IFI. Conclusion: Implementation of a standardised protocol with posaconazole as the primary agent was associated with increased use of antifungal prophylaxis among patients undergoing induction/reinduction chemotherapy for haematologic malignancies in our hospital. Lack of antifungal prophylaxis was an independent predictor of IFIs, underscoring the importance of prophylaxis in this at‐risk population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
- Author
-
Issa, Jean-Pierre J, Roboz, Gail, Rizzieri, David, Jabbour, Elias, Stock, Wendy, O'Connell, Casey, Yee, Karen, Tibes, Raoul, Griffiths, Elizabeth A, Walsh, Katherine, Daver, Naval, Chung, Woonbok, Naim, Sue, Taverna, Pietro, Oganesian, Aram, Hao, Yong, Lowder, James N, Azab, Mohammad, Kantarjian, Hagop, and O'Connell, Casey
- Subjects
- *
MYELODYSPLASTIC syndromes , *ACUTE myeloid leukemia , *BONE marrow diseases , *PRELEUKEMIA , *ONCOLOGY , *MEDICAL care , *ANTINEOPLASTIC agents , *CLINICAL trials , *COMPARATIVE studies , *DRUG dosage , *DOSE-effect relationship in pharmacology , *DRUG toxicity , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *RESEARCH funding , *STATISTICAL sampling , *TUMOR classification , *EVALUATION research , *RANDOMIZED controlled trials , *AZACITIDINE - Abstract
Background: Hypomethylating agents are used to treat cancers driven by aberrant DNA methylation, but their short half-life might limit their activity, particularly in patients with less proliferative diseases. Guadecitabine (SGI-110) is a novel hypomethylating dinucleotide of decitabine and deoxyguanosine resistant to degradation by cytidine deaminase. We aimed to assess the safety and clinical activity of subcutaneously given guadecitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.Methods: In this multicentre, open-label, phase 1 study, patients from nine North American medical centres with myelodysplastic syndrome or acute myeloid leukaemia that was refractory to or had relapsed after standard treatment were randomly assigned (1:1) to receive subcutaneous guadecitabine, either once-daily for 5 consecutive days (daily × 5), or once-weekly for 3 weeks, in a 28-day treatment cycle. Patients were stratified by disease. A 3 + 3 dose-escalation design was used in which we treated patients with guadecitabine doses of 3-125 mg/m(2) in separate dose-escalation cohorts. A twice-weekly treatment schedule was added to the study after a protocol amendment. The primary objective was to assess safety and tolerability of guadecitabine, determine the maximum tolerated and biologically effective dose, and identify the recommended phase 2 dose of guadecitabine. Safety analyses included all patients who received at least one dose of guadecitabine. Pharmacokinetic and pharmacodynamic analyses to determine the biologically effective dose included all patients for whom samples were available. This study is registered with ClinicalTrials.gov, number NCT01261312.Findings: Between Jan 4, 2011, and April 11, 2014, we enrolled and treated 93 patients: 35 patients with acute myeloid leukaemia and nine patients with myelodysplastic syndrome in the daily × 5 dose-escalation cohorts, 28 patients with acute myeloid leukaemia and six patients with myelodysplastic syndrome in the once-weekly dose-escalation cohorts, and 11 patients with acute myeloid leukaemia and four patients with myelodysplastic syndrome in the twice-weekly dose-escalation cohorts. The most common grade 3 or higher adverse events were febrile neutropenia (38 [41%] of 93 patients), pneumonia (27 [29%] of 93 patients), thrombocytopenia (23 [25%] of 93 patients), anaemia (23 [25%] of 93 patients), and sepsis (16 [17%] of 93 patients). The most common serious adverse events were febrile neutropenia (29 [31%] of 93 patients), pneumonia (26 [28%] of 93 patients), and sepsis (16 [17%] of 93 patients). Six of the 74 patients with acute myeloid leukaemia and six of the 19 patients with myelodysplastic syndrome had a clinical response to treatment. Two dose-limiting toxicities were noted in patients with myelodysplastic syndrome at 125 mg/m(2) daily × 5, thus the maximum tolerated dose in patients with myelodysplastic syndrome was 90 mg/m(2) daily × 5. The maximum tolerated dose was not reached in patients with acute myeloid leukaemia. Potent dose-related DNA demethylation occurred on the daily × 5 regimen, reaching a plateau at 60 mg/m(2) (designated as the biologically effective dose).Interpretation: Guadecitabine given subcutaneously at 60 mg/m(2) daily × 5 is well tolerated and is clinically and biologically active in patients with myelodysplastic syndrome and acute myeloid leukaemia. Guadecitabine 60 mg/m(2) daily × 5 is the recommended phase 2 dose, and these findings warrant further phase 2 studies.Funding: Astex Pharmaceuticals, Stand Up To Cancer. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
34. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.
- Author
-
Horwitz, Mitchell E., Chao, Nelson J., Rizzieri, David A., Long, Gwynn D., Sullivan, Keith M., Gasparetto, Cristina, Chute, John P., Morris, Ashley, McDonald, Carolyn, Waters-Pick, Barbara, Stiff, Patrick, Wease, Steven, Peled, Amnon, Snyder, David, Cohen, Einat Galamidi, Shoham, Hadas, Landau, Efrat, Friend, Etty, Peleg, Iddo, and Aschengrau, Dorit
- Subjects
- *
CORD blood transplantation , *CORD blood , *HEMATOPOIESIS , *NEUTROPHILS , *NICOTINAMIDE - Abstract
Background. Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to be demonstrated. We tested the hypothesis that a UCB-derived cell product consisting of stem cells expanded for 21 days in the presence of nicotinamide and a noncultured T cell fraction (NiCord) can accelerate hematopoietic recovery and provide long-term engraftment. Methods. In a phase I trial, 11 adults with hematologic malignancies received myeloablative bone marrow conditioning followed by transplantation with NiCord and a second unmanipulated UCB unit. Safety, hematopoietic recovery, and donor engraftment were assessed and compared with historical controls. Results. No adverse events were attributable to the infusion of NiCord. Complete or partial neutrophil and T cell engraftment derived from NiCord was observed in 8 patients, and NiCord engraftment remained stable in all patients, with a median follow-up of 21 months. Two patients achieved long-term engraftment with the unmanipulated unit. Patients transplanted with NiCord achieved earlier median neutrophil recovery (13 vs. 25 days, P < 0.001) compared with that seen in historical controls. The 1-year overall and progression-free survival rates were 82% and 73%, respectively. Conclusion. UCB-derived hematopoietic stem and progenitor cells expanded in the presence of nicotinamide and transplanted with a T cell-containing fraction contain both short-term and long-term repopulating cells. The results justify further study of NiCord transplantation as a single UCB graft. If long-term safety is confirmed, NiCord has the potential to broaden accessibility and reduce the toxicity of UCB transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.
- Author
-
Frankel, Arthur, Liu, Jen-Sing, Rizzieri, David, and Hogge, Donna
- Subjects
- *
ACUTE myeloid leukemia , *DIPHTHERIA , *INTERLEUKIN-3 , *MYELODYSPLASTIC syndromes , *PHARMACODYNAMICS - Abstract
DT388IL3 fusion protein containing the catalytic and translocation domains of diphtheria toxin fused to human interleukin 3 was administered in an inter-patient dose escalation trial by 15 min i.v. infusions every other day for up to 6 doses to patients with chemo-refractory acute myeloid leukemia (AML) and myelodysplasia (MDS). The maximal tolerated dose was >12.5 µg/kg/dose. Transient grade 3 transaminasemia and grade 2 fevers, chills, hypoalbuminemia, and hypotension occurred. Peak DT388IL3 levels correlated with dose and day of administration but not antibody titer. Anti-DT388IL3 antibodies developed in most patients between day 15 and 30. Of 40 evaluable AML patients, 1 had a CR (8 months) and 1 had PR (3 months). Of 5 MDS patients, 1 had a PR (4 months). Because of the prolonged infusion schedule, many patients failed to receive six doses. DT388IL3 produces remissions in patients with relapsed/refractory AML and MDS with minimal toxicities, and alternate schedules of administration are needed to enhance the response rate. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
36. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
- Author
-
Dannull, Jens, Su, Zhen, Rizzieri, David, Yang, Benjamin K., Coleman, Doris, Yancey, Donna, Zhang, Aijing, Dahm, Philipp, Chao, Nelson, Gilboa, Eli, and Vieweg, Johannes
- Subjects
- *
CANCER treatment , *T cells , *LYMPHOCYTES , *PREVENTION of communicable diseases , *IMMUNIZATION , *DIPHTHERIA toxin , *RENAL cancer , *RENAL cell carcinoma , *RNA metabolism , *TUMOR treatment , *KIDNEY tumors , *ANTIGENS , *BACTERIAL toxins , *CELL receptors , *CELL separation , *CLINICAL trials , *COMPARATIVE studies , *DENDRITIC cells , *ENZYME-linked immunosorbent assay , *FLOW cytometry , *GENETIC techniques , *IMMUNOSUPPRESSIVE agents , *INTERFERONS , *INTERLEUKIN-2 , *INTERLEUKINS , *RESEARCH methodology , *MEDICAL cooperation , *METASTASIS , *POLYMERASE chain reaction , *RESEARCH , *RESEARCH funding , *RNA , *TIME , *TUMOR antigens , *TUMORS , *CANCER vaccines , *EVALUATION research , *REVERSE transcriptase polymerase chain reaction , *MONONUCLEAR leukocytes , *PHARMACODYNAMICS - Abstract
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB(389)IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing the immunostimulatory efficacy of tumor RNA-transfected DC vaccines. We show that DAB(389)IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25. DAB(389)IL-2-mediated Treg depletion resulted in enhanced stimulation of proliferative and cytotoxic T cell responses in vitro but only when DAB(389)IL-2 was omitted during T cell priming. DAB(389)IL-2 significantly reduced the number of Tregs present in the peripheral blood of metastatic renal cell carcinoma (RCC) patients and abrogated Treg-mediated immunosuppressive activity in vivo. Moreover, DAB(389)IL-2-mediated elimination of Tregs followed by vaccination with RNA-transfected DCs significantly improved the stimulation of tumor-specific T cell responses in RCC patients when compared with vaccination alone. Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
37. Radioimmunotherapy for Non-Hodgkin's Lymphoma.
- Author
-
Rao, Arati V., Akabani, Gamal, and Rizzieri, David A.
- Subjects
- *
HODGKIN'S disease , *BLOOD diseases , *DRUG therapy , *IMMUNOTHERAPY , *MONOCLONAL antibodies , *RADIOISOTOPES - Abstract
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in the United States with a rapidly increasing incidence. Most follicular NHL is indolent but incurable, whereas the more aggressive varieties do respond to therapy. Most patients with follicular NHL who transform to an aggressive NHL are very difficult to treat successfully. Treatment options have included chemotherapy, radiation, immunotherapy with monoclonal antibodies, alone or in combination, and hematopoietic stem cell transplantation. The efficacy of monoclonal antibodies is augmented when they are combined with a radioisotope like iodine-131 or yttrium-90. There have been a number of studies done in recent years studying the efficacy of this form of therapy, i.e., radioimmunotherapy (RIT) in patients with NHL. This review attempts to integrate the information from the various clinical trials done using RIT in patients with relapsed/refractory or newly diagnosed NHL and in hematopoietic stem cell transplantation. It also includes updates on the use of RIT in elderly patients and in patients with significant bone marrow involvement among other recent advances made in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
38. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
- Author
-
Kantarjian, Hagop M., Begna, Kebede H., Altman, Jessica K., Goldberg, Stuart L., Sekeres, Mikkael A., Strickland, Stephen A., Arellano, Martha L., Claxton, David F., Baer, Maria R., Gautier, Marc, Berman, Ellin, Seiter, Karen, Solomon, Scott R., Schiller, Gary J., Luger, Selina M., Butrym, Aleksandra, Gaidano, Gianluca, Thomas, Xavier G., Montesinos, Pau, and Rizzieri, David A.
- Subjects
- *
ACUTE myeloid leukemia , *OLDER patients , *LEUKOCYTE count , *DIAGNOSIS , *DISEASE remission , *OVERALL survival - Abstract
Background: Acute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alternating cycles with decitabine, a low‐intensity therapy, to elderly patients with newly diagnosed AML. Methods: This randomized, open‐label, phase 3 study (SEAMLESS) was conducted at 87 sites in 11 countries. Patients aged ≥70 years who were not candidates for or chose not to receive standard induction chemotherapy were randomized 1:1 to arm A (decitabine in alternating cycles with sapacitabine) received 1‐hour intravenous infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 8 weeks (first cycle and subsequent odd cycles) and sapacitabine 300 mg twice daily on 3 consecutive days per week for 2 weeks every 8 weeks (second cycle and subsequent even cycles) or to control arm C who received 1‐hour infusions of decitabine 20 mg/m2 once daily for 5 consecutive days every 4 weeks. Prior hypomethylating agent therapy for preexisting myelodysplastic syndromes or myeloproliferative neoplasms was an exclusion criterion. Randomization was stratified by antecedent myelodysplastic syndromes or myeloproliferative neoplasms, white blood cell count (<10 × 109/L and ≥10 × 109/L), and bone marrow blast percentage (≥50% vs <50%). The primary end point was overall survival (OS). Secondary end points were the rates of complete remission (CR), CR with incomplete platelet count recovery, partial remission, hematologic improvement, and stable disease along with the corresponding durations, transfusion requirements, number of hospitalized days, and 1‐year survival. The trial is registered at ClinicalTrials.gov (NCT01303796). Results: Between October 2011 and December 2014, 482 patients were enrolled and randomized to receive decitabine administered in alternating cycles with sapacitabine (study arm, n = 241) or decitabine monotherapy (control arm, n = 241). The median OS was 5.9 months on the study arm versus 5.7 months on the control arm (P =.8902). The CR rate was 16.6% on the study arm and 10.8% on the control arm (P =.1468). In patients with white blood cell counts <10 × 109/L (n = 321), the median OS was higher on the study arm versus the control arm (8.0 vs 5.8 months; P =.145), as was the CR rate (21.5% vs 8.6%; P =.0017). Conclusions: The regimen of decitabine administered in alternating cycles with sapacitabine was active but did not significantly improve OS compared with decitabine monotherapy. Subgroup analyses suggest that patients with baseline white blood cell counts <10 × 109/L might benefit from decitabine alternating with sapacitabine, with an improved CR rate and the convenience of an oral drug. These findings should be prospectively confirmed. The regimen of decitabine administered in alternating cycles with sapacitabine is active but does not significantly improve overall survival compared with decitabine monotherapy. Subgroup analyses suggest that patients with baseline white blood cell counts <10 × 109/L might benefit from decitabine alternating with sapacitabine, which has an improved complete remission rate and the convenience of an oral drug; these findings should be prospectively confirmed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma.
- Author
-
McCune, Steven L., Gockerman, Jon P., and Rizzieri, David A.
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *LYMPHOMA treatment , *IMMUNOGLOBULINS , *THERAPEUTICS - Abstract
Focuses on monoclonal antibodies and how they can be used to treat illnesses, including Non-Hodgkin lymphoma (NHL). How monoclonal antibodies are believed to kill tumors through three mechanisms; Treatment of patients with follicular NHL with the monoclonal antibody rituximab; Limitations on the use of the antibodies; Questions surrounding the future use of monoclonal antibodies.
- Published
- 2001
- Full Text
- View/download PDF
40. A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
- Author
-
Borthakur, Gautam, Odenike, Olatoyosi, Aldoss, Ibrahim, Rizzieri, David A., Prebet, Thomas, Chen, Chris, Popovic, Relja, Modi, Dimple A., Joshi, Rujuta H., Wolff, Johannes E., and Jonas, Brian A.
- Subjects
- *
ACUTE myeloid leukemia , *VENETOCLAX , *CYTARABINE , *CARCINOGENESIS , *ONCOLOGY , *CANCER genes - Abstract
Background: Acute myeloid leukemia (AML) is a heterogenous malignancy driven by genetic and epigenetic factors. Inhibition of bromodomain and extraterminal (BET) proteins, epigenetic readers that play pivotal roles in the regulation of genes relevant to cancer pathogenesis, constitutes a novel AML treatment approach. Methods: In this first‐in‐human study of the pan‐BET inhibitor mivebresib as monotherapy (MIV‐mono) or in combination with venetoclax (MIV‐Ven), the safety profile, efficacy, and pharmacodynamics of mivebresib were determined in patients with relapsed/refractory AML (ClinicalTrials.gov identifier NCT02391480). Mivebresib was administered at 3 monotherapy dose levels (1.5, 2.0, or 2.5 mg) or in combination with venetoclax (400 or 800 mg). Results: Forty‐four patients started treatment: of 19 who started MIV‐mono, 5 went on to receive MIV‐Ven combination therapy after disease progression and a washout period. Twenty‐five patients started MIV‐Ven, resulting in a total of 30 patients treated with the combination. The most common mivebresib‐related treatment‐emergent adverse events were dysgeusia (74%), decreased appetite (42%), and diarrhea (42%) in the MIV‐mono group and decreased appetite (44%), vomiting (44%), and nausea (40%) in the MIV‐Ven group. Serious adverse events occurred in 14 patients (74%) who received MIV‐mono and in 22 patients (88%) who received MIV‐Ven. In the MIV‐mono group, responses were complete remission with incomplete blood count recovery in 1 patient and resistant disease in 15 patients. In the MIV‐Ven group, responses were complete remission in 2 patients, partial remission in 2 patients, morphologic leukemia‐free state in 2 patients, resistant disease in 12 patients, and aplasia in 1 patient. The pharmacodynamic effects of mivebresib were proportional to dose and drug exposure. Conclusions: Mivebresib was tolerated and showed antileukemic effects as monotherapy and in combination with venetoclax in patients with relapsed/refractory AML. Lay Summary: Mivebresib is a novel drug that influences the way cancer cells read genetic information. Mivebresib was tested together with venetoclax in patients with acute myeloid leukemia after standard medicines failed and the disease returned, or when standard medicine was unavailable. Adverse effects were described for different drug doses, and the dose that is tolerable was determined. In some patients, their leukemia improved for some time. More studies are necessary to determine whether mivebresib can be used to treat acute myeloid leukemia. Mivebresib is tolerable and produces antileukemic effects as monotherapy and when combined with venetoclax in patients who have relapsed/refractory acute myeloid leukemia. Mivebresib also demonstrates a statistically significant dose‐dependent correlation between biomarker modulation and drug exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Phase I, Dose Escalation Study of Naïve T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation.
- Author
-
Maung, Ko Ko, Chen, Benny J, Rizzieri, David A, Gasparetto, Cristina, Sullivan, Keith, Long, Gwynn D, Engemann, Ashley Morris, Waters-Pick, Barbara, Nichols, Krista Rowe, Lopez, Richard, Kang, Yubin, Sarantopoulos, Stefanie, Sung, Anthony D., Chao, Nelson J., and Horwitz, Mitchell E.
- Subjects
- *
STEM cell transplantation , *T cells , *LYMPHOCYTES , *CANCER relapse , *HLA histocompatibility antigens - Abstract
Introduction Prophylactic, donor lymphocyte infusion (DLI) is used to augment immune recovery and graft vs. tumor effect following a T-cell depleted alloSCT. However, it carries the risk of inducing severe GvHD. Our pre-clinical murine studies have implicated the naive T-cell, defined by CD62L marker, as the primary driver of alloreactivity. We hypothesize that transferring selected memory T-cells without naive-T cells would endow the patient with cells that do not cause GvHD while augmenting host defense against infection and tumor recurrence. Objectives The goal of the study was to determine the maximum tolerated dose of a prophylactic, delayed DLI that has been depleted of naive T-cells. Methods We enrolled 16 adult patients, median age 54 who met following criteria; a. underwent an alemtuzumab or thymoglobulin-containing non-myeloablative allogeneic transplant from an HLA-identical family donor or an 8/8 HLA-matched unrelated donor (MUD), b. at least 60 days from day of transplantation, c. no active acute GvHD grade II or higher. Primary diseases were CLL; n=1, MM; n=2, MF; n=1, NHL; n=5, MDS; n=1, AML; n=6. A dedicated, non-mobilized donor apheresis procedure was performed following enrollment. Naive, CD45RA+ T-cells were depleted from the collection under an IND using the Miltenyi clinimacs system. A standard phase I, 3+3 dose escalation schema was employed. The dose-limiting toxicity of the DLI was defined as development of grade III/IV acute GvHD within 90 days of the DLI. Results The DLI was infused on median 112.5 days (76 to 280 days) following transplant. 8 patients received matched sibling grafts and 8 received MUD grafts. 3 patients each received naive T-cell depleted CD3+ dose of 1 × 105/kg, 1 × 106/kg, and 5 × 106/kg. The top dose of 1 × 107/kg was expanded to 7 patients. No dose limiting toxicity or adverse event attributable to the DLI was observed at any dose level. 1 patient developed grade 2 acute GvHD and 1 developed moderate chronic GvHD attributable to the DLI. 4 patients had relapsed disease; 2 in the lowest dose and 2 in the highest dose levels. With a median follow-up of 2.75 years, 2-year relapse free and overall survivals are 56.25% and 68.75%, respectively (Fig 1 and 2). NK cells, CD3+T lymphocytes, CD4+ T lymphocytes and CD8+ T lymphocytes show positive correlations of 0.24, 0.40, 0.42 and 0.38 respectively with time following the DLI (Fig 3). Conclusion A prophylactic, naive T-cell depleted DLI can be provided safely, without significant risk of acute GvHD at a dose of 1 × 10e7 CD3/kg. Larger studies in a more homogeneous patient population will be needed to confirm the impact on immune recovery and relapse prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
42. Clinical and Neuroimaging Correlates of Post-Transplant Delirium.
- Author
-
Smith, Patrick, Thompson, Jillian C., Perea, Elena, Wasserman, Brian, Bohannon, Lauren, Racioppi, Alessandro, Choi, Taewoong, Gasparetto, Cristina, Horwitz, Mitchell E., Long, Gwynn, Lopez, Richard, Rizzieri, David A., Sarantopoulos, Stefanie, Sullivan, Keith M., Chao, Nelson J., and Sung, Anthony D.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *DELIRIUM , *WHITE matter (Nerve tissue) , *CEREBRAL atrophy , *BRAIN imaging - Abstract
• Delirium is common following hematopoietic stem cell transplantation. • In this select sample, greater age, treatment regimen intensity, and greater white matter burden were all associated with greater delirium incidence. Delirium is common among adults undergoing hematopoietic stem cell transplantation (HCT), although the clinical and neuroimaging correlates of post-HCT delirium have not been adequately delineated. We therefore examined the frequency of delirium and neuroimaging correlates of post-transplant delirium in a retrospective cohort of 115 adults undergoing neuroimaging after allogeneic HCT. Delirium was established using previously validated methods for retrospective identification of chart-assessed postprocedural delirium. Chart reviews were independently conducted by a multidisciplinary team with expertise in HCT, psychiatry, and psychology on consecutive allogeneic HCT patients who underwent neuroimaging assessments and transplantation at a single center between January 2009 and December 2016. Neuroimaging markers of white matter damage and brain volume loss were also recorded. In total, 115 patients were included, ranging in age from 20 to 74 years (mean [SD] age, 49 [13]). Fifty-three patients (46%) developed post-HCT delirium. In an adjusted model, delirium incidence was associated with older age (odds ratio [OR], 1.92 [1.28, 2.87] per decade, P =.002), greater severity of white matter hyperintensities (OR, 1.95 [1.06, 3.57], P =.031), and conditioning intensity (OR, 6.37 [2.20, 18.45], P <.001) but was unrelated to cortical atrophy (P =.777). Delirium was associated with fewer hospital-free days (P =.023) but was not associated with overall survival (hazard ratio, 0.95 [0.56, 1.61], P =.844). Greater incidence of delirium following HCT was associated with greater age, microvascular burden, and conditioning intensity. Pre-HCT consideration of microvascular burden and other neuroimaging biomarkers of risk may be warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
43. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.
- Author
-
Solomon, Scott R., Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J., Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, and Solh, Melhem
- Subjects
- *
CORD blood transplantation , *CORD blood , *HEMATOLOGIC malignancies , *AFRICAN Americans , *ACUTE myeloid leukemia - Abstract
• The use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation is regardless of patient race or ethnicity. • The risk of grade II-IV and III-IV acute graft-versus-host disease is increased after umbilical cord blood transplantation. • The risk of transplantation-related mortality is increased with umbilical cord blood transplantation. Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P <.0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P =.008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P =.51), overall survival (54% versus 57%; P =.66), or disease-free survival (43% versus 47%; P =.46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
- Author
-
Goldberg, Aaron D., Atallah, Ehab, Rizzieri, David, Walter, Roland B., Chung, Ki-Young, Spira, Alexander, Stock, Wendy, Tallman, Martin S., Cruz, Hans G., Boni, Joseph, Havenith, Karin E.G., Chao, Grace, Feingold, Jay M., Wuerthner, Jens, and Solh, Melhem
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *ACUTE myeloid leukemia , *ANTIBODY-drug conjugates , *CYTARABINE , *CD25 antigen , *APOPTIN , *LYMPHOPENIA - Abstract
The mechanism of action of camidanlumab tesirine. Camidanlumab tesirine binds to the CD25 antigen on AML/ALL tumor cells. Upon binding, the ADC is internalized and releases PBD dimers after the protease-sensitive linker is cleaved in lysosomes. The released PBD molecules migrate into the nucleus and sequence-selectively bind to the DNA minor groove, forming inter-strand cross-links that block tumor cell division and, hence, directly kill the cell. ADC, antibody-drug conjugate; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; PBD, pyrrolobenzodiazepine. • Camidanlumab tesirine demonstrated an acceptable safety and tolerability profile in adults with R/R CD25+ ALL or AML. • The maximum tolerated dose was not reached at the investigated doses, with only one dose-limiting toxicity observed. • Camidanlumab tesirine demonstrated modest efficacy, with two complete remissions in patients with R/R CD25+ AML with a weekly dosing schedule • These results warrant possible further investigation of camidanlumab tesirine and/or combination treatments in patients with R/R CD25+ acute leukemia. There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation and -expansion study (NCT02588092) assessed the safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory ALL/AML. A total of 35 patients (34 AML and 1 ALL) were enrolled and received camidanlumab tesirine intravenously at 3–92 μg/kg once every three weeks (Q3W, n = 26) or 30 or 37.5 μg/kg every week (QW, n = 9). One dose-limiting toxicity of maculopapular rash occurred in the 30 μg/kg QW group; the maximum tolerated dose was not reached. No additional safety concerns or adverse events (AEs) of interest were identified. The most common (>10 % of patients) Grade ≥3 treatment-emergent AEs were febrile neutropenia (25.7 %), lymphopenia, neutropenia, thrombocytopenia or fatigue (all 14.3 %), pneumonia, increased gamma-glutamyltransferase, and hypophosphatemia (each 11.4 %). No signal for serious immune-related AEs such as Guillain-Barré syndrome/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life <2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule. Two patients achieved complete responses with incomplete hematologic recovery; one each at 30 and 37.5 μg/kg QW. The trial was terminated during dose escalation due to programmatic reasons other than safety. Hence, recommended dose was not determined. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
45. Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.
- Author
-
Maung, Ko, Ramalingam, Sendhilnathan, Chaudhry, Mohammad, Ren, Yi, Jung, Sin-Ho, Romero, Kristi, Corbet, Kelly, Chao, Nelson J., Choi, Taewoong, Diehl, Anna Mae, Diehl, Louis, Gasparetto, Cristina, Horwitz, Mitchell, Long, Gwynn Douglas, Lopez, Richard D., Rizzieri, David A., Sarantopoulos, Stefanie, Sullivan, Keith M., Bashir, Mustafa R., and Sung, Anthony D.
- Subjects
- *
FATTY liver , *FATTY degeneration , *GRAFT versus host disease , *CHRONIC diseases , *ACADEMIC medical centers - Abstract
Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We hypothesized that hepatic steatosis on pre-HCT computed tomography (CT) scans may be a marker for development of GVHD and poor outcomes in allo-HCT. In this retrospective study, we reviewed the pre-HCT CT scans and transplant outcome data of patients who underwent allo-HCT at Duke University Medical Center from 2009 to 2017. The presence of steatosis was confirmed using CT attenuation measurements. We then assessed the association between pre-HCT hepatic steatosis and HCT-related outcomes including GVHD. 80 patients who had pre-HCT CT scans were included in the study. Pre-transplant hepatic steatosis was associated with the development of chronic GVHD (OR 4.2, p = 0.02), but was not associated with acute GVHD (OR 1.3, p = 0.7), non-relapse mortality (p = 0.81) or overall survival (p = 0.74). Based on this single center retrospective study, pre-transplant hepatic steatosis is associated with development of chronic GVHD. Further, prospective study with other imaging modalities including non-contrasted CT scans is needed to determine if this association is reproducible. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
- Author
-
Berdeja, Jesus G., Heinrich, Michael C., Dakhil, Shaker R., Goldberg, Stuart L., Wadleigh, Martha, Kuriakose, Philip, Cortes, Jorge, Radich, Jerald, Helton, Bret, Rizzieri, David, Paley, Carole, Dautaj, Ilva, and Mauro, Michael J.
- Subjects
- *
CHRONIC myeloid leukemia , *NILOTINIB , *POLYMERASE chain reaction , *CARDIOVASCULAR diseases - Abstract
ENESTnext (NCT01227577) was a single-arm, multicenter trial evaluating the rate of deep molecular response by 2 years in patients with newly diagnosed (within 6 months) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib 300 mg twice daily. Among 128 enrolled patients, 94 (73%) achieved major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) and 34 (27%) achieved confirmed MR4.5 (BCR-ABL1IS ≤0.0032% detectable or undetectable; primary endpoint) by 2 years. Three-month BCR-ABL1 levels were predictive of later responses. In exploratory analyses, digital polymerase chain reaction (PCR) detected BCR-ABL1 in 39.4% of samples from patients with confirmed MR4.5 and identified further decreases in BCR-ABL1 with continued nilotinib. Safety results, including cardiovascular events, were consistent with those in other nilotinib trials. These results further substantiate the molecular response rates associated with frontline nilotinib therapy and demonstrate the feasibility of monitoring very low BCR-ABL1 transcript levels using digital PCR. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
47. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
- Author
-
Pemmaraju, Naveen, Lane, Andrew A., Sweet, Kendra L., Stein, Anthony S., Vasu, Sumithira, Blum, William, Rizzieri, David A., Wang, Eunice S., Duvic, Madeleine, Sloan, J. Mark, Spence, Sharon, Shemesh, Shay, Brooks, Christopher L., Balser, John, Bergstein, Ivan, Lancet, Jeffrey E., Kantarjian, Hagop M., and Konopleva, Marina
- Subjects
- *
EDEMA , *DIPHTHERIA toxin , *ALANINE aminotransferase , *ASPARTATE aminotransferase , *INTERLEUKIN-3 , *DENDRITIC cells , *ANTINEOPLASTIC agents , *CLINICAL trials , *COMPARATIVE studies , *DOSE-effect relationship in pharmacology , *RESEARCH methodology , *MEDICAL cooperation , *RECOMBINANT proteins , *RESEARCH , *EVALUATION research , *MYELOID leukemia , *CAPILLARY leak syndrome , *KAPLAN-Meier estimator - Abstract
Background: Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA or CD123). Tagraxofusp (SL-401) is a CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin.Methods: In this open-label, multicohort study, we assigned 47 patients with untreated or relapsed BPDCN to receive an intravenous infusion of tagraxofusp at a dose of 7 μg or 12 μg per kilogram of body weight on days 1 to 5 of each 21-day cycle. Treatment continued until disease progression or unacceptable toxic effects. The primary outcome was the combined rate of complete response and clinical complete response among patients who had not received previous treatment for BPDCN. A secondary outcome was the duration of response.Results: Of the 47 patients, 32 were receiving tagraxofusp as first-line treatment and 15 had received previous treatment. The median age of the patients was 70 years (range, 22 to 84). Among the 29 previously untreated patients who received tagraxofusp at a dose of 12 μg per kilogram, the primary outcome occurred in 21 (72%), and the overall response rate was 90%; of these patients, 45% went on to undergo stem-cell transplantation. Survival rates at 18 and 24 months were 59% and 52%, respectively. Among the 15 previously treated patients, the response rate was 67%, and the median overall survival was 8.5 months. The most common adverse events were increased levels of alanine aminotransferase (64%) and aspartate aminotransferase (60%), hypoalbuminemia (55%), peripheral edema (51%), and thrombocytopenia (49%). Capillary leak syndrome was reported in 19% of the patients and was associated with one death in each of the dose subgroups.Conclusions: In adult patients with untreated or relapsed BPDCN, the use of tagraxofusp led to clinical responses. Serious adverse events included capillary leak syndrome; hepatic dysfunction and thrombocytopenia were common. (Funded by Stemline Therapeutics and the Leukemia and Lymphoma Society Therapy Acceleration Program; ClinicalTrials.gov number, NCT02113982.). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
48. Fluoroquinolone prophylaxis reduces febrile neutropenia, bloodstream infections from mucosal translocations, and intensive care admissions in high risk hematological patients, a single center experience.
- Author
-
Miller, Rachel Ann, Permpalung, Nitipong, Baker, Arthur Wakefield, Alexander, Barbara Dudley, Chung, Shimin Jasmine, Diehl, Louis Frederic, and Rizzieri, David Alan
- Subjects
- *
FEBRILE neutropenia , *ENTEROCOCCUS , *MACROPHAGE colony-stimulating factor , *CRITICAL care medicine , *PREVENTIVE medicine - Abstract
The article focuses on the acute promyelocytic leukemia (APL) in elderly patients. It discusses the recommendations of the combination of chemotherapy with all-trans retinoic acid (ATRA), patient survival with the use of Kaplan-Maier method and log-rank test, and hematological complete remission (CR) rate.
- Published
- 2019
- Full Text
- View/download PDF
49. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
- Author
-
Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J., and O'Connell, Casey L
- Subjects
- *
ACUTE myeloid leukemia , *RANDOMIZED controlled trials , *ANTINEOPLASTIC agents , *CANCER chemotherapy , *DRUG efficacy , *COMPARATIVE studies , *DRUG administration , *HEMATOPOIETIC stem cell transplantation , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *DISEASE relapse , *EVALUATION research , *AZACITIDINE , *PHARMACODYNAMICS - Abstract
Background: Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next-generation hypomethylating agent, could be useful in treating such patients.Methods: In this multicenter, open-label, phase 2 dose-expansion study, AML patients from 10 North American medical centers were first randomized (1:1) to receive subcutaneous guadecitabine at 60 or 90 mg/m2 on 5 consecutive days in each 28-day cycle (5-day regimen). Subsequently, another cohort was treated for 10 days with 60 mg/m2 (10-day regimen).Results: Between June 15, 2012, and August 19, 2013, 108 patients with previously treated AML consented to enroll in the study, and 103 of these patients were treated; 5 patients did not receive the study treatment. A total of 103 patients were included in the safety and efficacy analyses (24 and 26 patients who were randomly assigned to 60 and 90 mg/m2 /d, respectively [5-day regimen] and 53 patients who were assigned to 60 mg/m2 /d [10-day regimen]). The 90 mg/m2 dose showed no benefit in clinical outcomes in comparison with 60 mg/m2 in the randomized cohort. Composite complete response (CRc) and complete response (CR) rates were higher with the 10-day regimen versus the 5-day regimen (CRc, 30.2% vs 16.0%; P = .1061; CR, 18.9% vs 8%; P = .15). Adverse events (grade ≥ 3) were mainly hematologic, with a higher incidence on the 10-day regimen. Early all-cause mortality was low and similar between regimens. Twenty patients (8 on the 5-day regimen and 12 on the 10-day regimen) were bridged to hematopoietic cell transplantation.Conclusions: Guadecitabine has promising clinical activity and an acceptable safety profile and thus warrants further development in this population. Cancer 2018;124:325-34. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
50. Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.
- Author
-
Anand, Sarah, Corbet, Kelly, Gasparetto, Cristina, Long, Gwynn D., Lopez, Richard, Morris, Ashley K., Rizzieri, David A., Sullivan, Keith M., Sung, Anthony D., Sarantopoulos, Stefanie, Chao, Nelson J., Horwitz, Mitchell E., and Thomas, Samantha
- Subjects
- *
CORD blood transplantation , *MYELOSUPPRESSION , *FLUDARABINE , *TOTAL body irradiation , *CYCLOPHOSPHAMIDE , *MORTALITY prevention , *THERAPEUTICS ,DISEASES in adults - Abstract
Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation (TBI), fludarabine, and cyclophosphamide regimen. In an attempt to reduce regimen-related toxicity, we previously studied a modified myeloablative regimen with TBI (1350 cGy) and fludarabine (160 mg/m 2 ); TRM was decreased, but neutrophil engraftment was suboptimal. Therefore, to improve engraftment while still minimizing regimen-related toxicity, we piloted a myeloablative regimen with the addition of thiotepa (10 mg/kg) to TBI and fludarabine conditioning. Thirty-one adult patients (median age, 46 years; range, 19 to 65) with hematologic malignancies (acute leukemia/myelodysplastic syndrome, 77%; lymphoid malignancy, 23%) underwent single (n = 1) or double (n = 30) UCBT from 2010 to 2015 at our institution. The cumulative incidence of neutrophil engraftment was 90% (95% confidence interval [CI], 70% to 97%) by 60 days, with a median time to engraftment of 21 days (95% CI, 19 to 26). The cumulative incidence of platelet engraftment was 77% (95% CI, 57% to 89%) by 100 days, with a median time to engraftment of 47 days (95% CI, 37 to 73). Cumulative incidences of grades II to IV and grades III to IV acute graft-versus-host disease (GVHD) at day 100 were 45% (95% CI, 27% to 62%) and 10% (95% CI, 2% to 23%), respectively. The overall incidence of chronic GVHD at 2 years was 40% (95% CI, 22% to 57%), with 17% of patients (95% CI, 6% to 33%) experiencing moderate to severe chronic GVHD by 2 years. TRM at 180 days was 13% (95% CI, 4% to 27%), at 1 year 24% (95% CI, 10% to 41%), and at 3 years 30% (95% CI, 13% to 49%). Relapse at 1 year was 13% (95% CI, 4% to 27%) and at 3 years 19% (95% CI, 6% to 38%). With a median follow-up of 35.5 months (95% CI, 12.7 to 52.2), disease-free and overall survival at 3 years were 51% (95% CI, 29% to 69%) and 57% (95% CI, 36% to 73%), respectively. This regimen represents a reasonable alternative to myeloablative conditioning with TBI, fludarabine, and cyclophosphamide and warrants further study. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.